Barbara Alicja Jereczek-Fossa
Overview
Explore the profile of Barbara Alicja Jereczek-Fossa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
302
Citations
2478
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bilski M, Korab K, Orzechowska M, Ponikowska J, Cisek P, Jereczek-Fossa B, et al.
Radiol Med
. 2025 Mar;
PMID: 40080327
Purpose: The standard treatment for oligometastatic colorectal cancer includes systemic therapy, with surgery and metastasis-directed therapy as options. The optimal strategy, especially for repeat oligoprogression (rOP), remains unclear. We report...
2.
Volpe S, Vincini M, Zaffaroni M, Gaeta A, Raimondi S, Piperno G, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075755
An Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patient candidate for stereotactic body radiotherapy (SBRT) may start their treatment without a histopathological assessment, due to relevant comorbidities. The aim of this...
3.
Corrao G, Marvaso G, Zaffaroni M, Vincini M, Badellino S, Borghetti P, et al.
Radiol Med
. 2025 Mar;
PMID: 40072805
Aim: Despite the widespread use of immunotherapy (IO) and targeted therapy (TT) in clinical practice, data on toxicity in combination with SBRT are lacking, largely based on retrospective studies and...
4.
Marvaso G, Corrao G, Zaffaroni M, Vincini M, Lorubbio C, Gandini S, et al.
Lancet Oncol
. 2025 Mar;
26(3):300-311.
PMID: 40049196
Background: Metastasis-directed therapy by stereotactic body radiotherapy (SBRT) has been shown to improve clinical outcomes in the oligometastatic prostate cancer setting. We aimed to investigate whether short-course androgen deprivation therapy...
5.
Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S, et al.
Prostate Cancer Prostatic Dis
. 2025 Feb;
PMID: 39972049
ARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate...
6.
Burla T, Zaffaroni M, Marvaso G, Mazzocco K, Galli G, Vincini M, et al.
Tumori
. 2025 Feb;
:3008916251317093.
PMID: 39924662
Purpose: Professional quality of life (QoL) is crucial for healthcare workers as it affects performance at work and interaction with patients, but little is known about stressors influencing radiation oncology...
7.
Rutkowski K, Gola M, Godlewski J, Starzynska A, Marvaso G, Mastroleo F, et al.
Oncol Rev
. 2025 Feb;
18:1514004.
PMID: 39906323
Worldwide, head and neck cancers (HNCs) account for approximately 900,000 cases and 500,000 deaths annually, with their incidence continuing to rise. Carcinogenesis is a complex, multidimensional molecular process leading to...
8.
Dangelillo R, Caffo O, Borsellino N, Cardone G, Colloca G, Conti G, et al.
Clin Genitourin Cancer
. 2025 Jan;
23(1):102292.
PMID: 39799764
The recent evidences provided in metastatic hormone sensitive prostate cancer (nmHSPC) and in nonmetastatic castration resistant (nmCRPC) introduced the possibility to adopt Androgen Receptor Signaling inhibitor (ARSi) alone (both settings)...
9.
Guerini A, Marvaso G, Tonoli S, Corrao G, Teriaca M, Sepulcri M, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796715
Methods And Materials: Patients with ongoing or planned anticancer treatment at 19 Italian Radiation Oncology centers were included in the study retrospectively from 3 February 2020 to 31 December 2020...
10.
Netti S, DEcclesiis O, Corso F, Botta F, Origgi D, Pesapane F, et al.
Eur Radiol
. 2024 Dec;
PMID: 39702630
Aim: To investigate whether methodological aspects may influence the performance of MRI-radiomic models to predict response to neoadjuvant treatment (NAT) in breast cancer (BC) patients. Materials And Methods: We conducted...